Advertisement

Topics

Mati Therapeutics Inc. Company Profile

23:01 EDT 18th June 2018 | BioPortfolio

Mati is developing PPDS, a sustained release ocular drug delivery platform that Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is inserted into a patient’s tear duct (or punctum). The device is already approved to treat dry eye syndrome, but Mati is the first to conduct clinical trials in the United States testing punctal plugs as an anchoring device for a drug delivery platform. A drug-eluting core is inserted into Mati’s proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time. Mati believes PPDS has the potential to become a more reliable alternative to several eye drop therapies, which can be ineffective because many patients are unwilling or unable to adhere to self-administered eye-drop regimens.


News Articles [784 Associated News Articles listed on BioPortfolio]

20,66 % - LONGi Solar établit un nouveau record mondial en matière d'efficience de conversion ...

Le Dr Lv Jun, vice-président de LONGi Solar, a déclaré : « Cette percée en matière d'efficience de conversion des modules vient confirmer davantage le potentiel de Read more...

LG Innotek présente une solution révolutionnaire en matière d'éclairage haut de gamme

La société a mis au point un boîtier LED à puce retournée haute qualité, qui améliore la fiabilité de façon notable, grâce aux toutes dernières Read more...

L'équipe d'Arkratos s'embarque sur une tournée européenne afin de faire la démonstration de ...

KRATOS, solution reposant sur les chaînes de blocs, vise à résoudre les défis opposés au secteur des échanges commerciaux sur les matières premières supports en Read more...

Les universités sud-africaines unissent leurs forces pour augmenter les effectifs ...

L'APFP est le programme phare en matière de formation d'infirmières postuniversitaires et de médecins pédiatres africains. Le professeur Ashraf Coovadia, Chef de service en Read more...

TTI réaffirme des performances en bonne voie pour la première moitié de 2018

Compte tenu de l'attention récente suscitée par l'inflation sur les matières premières, c'est avec plaisir que TTI signale que ses initiatives de productivité et les Read more...

iPoint s'empare du leader de l'industrie en matière d'évaluation de cycle de vie et de ...

iPoint-systems poursuit sa trajectoire de croissance. Depuis décembre 2017, ifu Institute for Environmental IT Hamburg est une filiale en propriété exclusive du groupe iPoint. L'entreprise de ...

HEVC Advance souligne son élan avec de tout nouveaux concédants et titulaires de licences

Le succès du programme augmente parallèlement à la réaction positive aux modifications en matière d'octroi de licences pour les distributeurs par streaming, câble, voie hertzienne Read more....

Hycor Biomedical demande le marquage CE pour NOVEOS™, son instrument de diagnostics in vitro ...

Moins d'exigences en matière d'échantillons :seul un volume de 4µL pour l'échantillon patient est nécessaire, ce qui peut être particulièrement important pour un échantillonnage Read ...

PubMed Articles [414 Associated PubMed Articles listed on BioPortfolio]

Investigation of sedimentation rates and sediment dynamics in Danube Delta lake system (Romania) by Pb dating method.

Being a dynamic environment associated with complex costal, fluvial and marine processes, only a few studies regarding the evolution of the Danube Delta and the human impacts on its ecosystem have bee...

No 354 - Lignes directrices canadiennes en matière de planification de la grossesse en présence du VIH.

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1240 Associated Companies listed on BioPortfolio]

Mati Therapeutics, Inc.

Mati is developing the Evolute® sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications. The platform utilizes a d...

Mati Therapeutics Inc.

Mati is developing PPDS, a sustained release ocular drug delivery platform that Mati believes has the potential to treat a range of ocular indications. The platform utilizes a dev...

Cible Communication sa

Choix des matières, respect des prérogatives clients, confidentialité, contrôle de la qualité, relations avec les fournisseurs et sélection de l'outsourcing… La production est également une d...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Mati Therapeutics Inc." on BioPortfolio

We have published hundreds of Mati Therapeutics Inc. news stories on BioPortfolio along with dozens of Mati Therapeutics Inc. Clinical Trials and PubMed Articles about Mati Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mati Therapeutics Inc. Companies in our database. You can also find out about relevant Mati Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record